Evaluation Of The Efficacy And Safety Of Using Chemical Sealing Agent In Reinforcement Of Stable Line In Laparoscopic Sleeve Gastrectomy

Hassan, Hisham Wefky Anwar; Morsy, Tarek Zaghloul Mohammed; Ahmed, Mohamed Awwad Selim

doi:https://doi.org/10.21608/aimj.2025.446677

Evaluation Of The Efficacy And Safety Of Using Chemical Sealing Agent In Reinforcement Of Stable Line In Laparoscopic Sleeve Gastrectomy

Document Type : Original Article

Authors

¹ Professor of General Surgery, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

² Lecturer of General Surgery, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

³ MBBCh, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

https://doi.org/10.21608/aimj.2025.446677

Abstract

Background: Worldwide, the epidemic of morbid obesity is posing a serious threat to public health. Bariatric surgery is still the go-to option for many patients after they've tried and failed with more conservative treatments, including changing their eating habits, increasing their physical activity, and improving their overall lifestyle.
Aim: In order to determine whether the use of Glubran, a chemical sealing agent, to reinforce the stable line during laparoscopic sleeve gastrectomy (LSG) is safe and effective in preventing early complications such as leaks and bleeding.
Subjects and methods: From September 2024 to March 2025, 25 patients with BMIs more than 40 who had LSG at the General Surgery Department, Al-Hussien and Sayed Galal, Al-Azhar University Hospitals in Cairo, participated in this combined prospective and retrospective cohort study.
Results: At 3months postoperative, Group-2 appears to have a higher prevalence of all symptoms compared to Group-1. In all examined symptoms (nausea, vomiting, fluid intolerance, heartburn, dyspepsia, dysphagia, regurgitation, and chest pain) at three months after surgery, a statistically significant p-value was found between the groups. In terms of nausea, heartburn, regurgitation, and chest discomfort, Group-2 seemed to have a larger prevalence of symptoms than Group-1 at six months after surgery. In terms of nausea, heartburn, regurgitation, and chest discomfort, Group-2 seemed to have a larger prevalence of symptoms than Group-1 at 12 months after surgery.
Conclusion: Both omentopexy with Glubran and gastrectomy (SG) are safe operations. The risk of problems like torsion, volvulus, and stomach tube blockage can be decreased using omentopexy. Additionally, it reduces the rate of leaks and hemorrhages and helps with postoperative nausea and vomiting.

Keywords